ClinicalTrials.gg
RecruitingNCT06788990FORTIFI-HN01Updated Oct 29, 2026

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

A Phase 2/3 interventional study of Ficerafusp alfa and Pembrolizumab (KEYTRUDA®) in Metastatic Head and Neck Squamous Cell Carcinoma and Recurrent Head and Neck Squamous Cell Carcinoma, sponsored by Bicara Therapeutics. Recruiting at 231 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Bicara Therapeutics · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 29, 2026First sites in Japan and Thailand230 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
26th of 993
650 · median 41
Started
2025
with 60 others
Phase 2/3
12 of 1,099
4 open now
Primary completion
2028-04
later than 232 of 346 live
Registered
1,001st of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 26th largest by planned enrollment of the 993 interventional ones that give a count, is one of 61 that started in 2025, is one of 12 in phase 2/3, reaches primary completion later than 232 of the 346 other live ones, and was the 1,001st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).

This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Read the detailed description

The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.

Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:

  • Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
  • Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
  • Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.

The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.

03

Conditions studied

  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma

Keywords

  • Phase 2/3
  • Ficerafusp alfa
  • BCA101
  • Recurrent Head and Neck Squamous Cell Carcinoma (R HNSCC)
  • Metastatic Head and Neck Squamous Cell Carcinoma (M HNSCC)
  • Pembrolizumab
  • EGFR
  • TGF-beta
  • HNSCC
  • PD-L1+
  • Head and Neck cancer
  • Oral Cavity
  • Oropharynx
  • Larynx
  • Hypopharynx
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years on the day the Form is signed.
  • or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
  • No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the or definitive setting.
  • or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
  • CPS ≥1.
  • based on 1.1.
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function, as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Disease suitable for local therapy administered with curative intent.
  • Prior treatment with anti-TGFβ therapy.
  • Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
  • Prior history of Grade ≥2 intolerance or reaction to anti-EGFR therapy or other murine proteins.
  • Prior therapy with an completed within 6 months prior to study treatment initiation.
  • Progressive disease \<6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
  • less than 3 months.
  • Known active central nervous system , history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or are excluded.
  • Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
  • Subject participated in another clinical study or received treatment with another drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
  • Active disease requiring systemic treatment in the past 2 years.
  • Subjects with chronic virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
  • Subjects with a known history of virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
  • Known history of (HIV).
  • Receipt of any organ transplantation, including and allogeneic stem cell transplantation, with the exception of transplants that do not require .
  • Known to be diagnosed and/or treated for any other additional within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
  • Any condition requiring systemic treatment with either (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
  • Use of a live or within 4 weeks prior to Screening.

Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Phase 2 Arm A

    ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)

    Drug: Ficerafusp alfa · Drug: Pembrolizumab (KEYTRUDA®)

  • Experimental
    Phase 2 Arm B

    ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W

    Drug: Ficerafusp alfa · Drug: Pembrolizumab (KEYTRUDA®)

  • Placebo comparator
    Phase 2 Arm C

    placebo QW + pembrolizumab 200 mg Q3W

    Drug: Pembrolizumab (KEYTRUDA®) · Drug: Placebo

  • Experimental
    Phase 3 OBD Arm

    ficerafusp alfa OBD + pembrolizumab 200 mg Q3W

    Drug: Ficerafusp alfa · Drug: Pembrolizumab (KEYTRUDA®)

  • Placebo comparator
    Phase 3 Arm C

    placebo QW + pembrolizumab 200 mg Q3W

    Drug: Pembrolizumab (KEYTRUDA®) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.

    To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

    Time frame: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

  2. Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)

    ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

    Time frame: Approximately 1 year.

  3. Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.

    ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

    Time frame: Approximately 2 years.

  4. Phase 3 - Overall Survival (OS)

    OS: Defined as the time from the randomization to death due to any cause.

    Time frame: Approximately 3 years.

Secondary outcomes

  1. Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.

    DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR.

    Time frame: Approximately 1 year.

  2. Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.

    To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

    Time frame: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

  3. Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.

    PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first.

    Time frame: Approximately 3 years.

  4. Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.

    ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).

    Time frame: Approximately 3 years.

  5. Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.

    DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR.

    Time frame: Approximately 3 years.

  6. Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.

    Clinical Benefit Rate: For subject who demonstrated CR + PR + SD\>6 months per RECIST 1.1 by BICR.

    Time frame: Approximately 3 years.

  7. Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.

    ORR, per RECIST 1.1 as determined by investigator's assessment.

    Time frame: Approximately 3 years.

  8. Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.

    DOR, per RECIST 1.1 as determined by investigator's assessment.

    Time frame: Approximately 3 years.

  9. Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.

    PFS, per RECIST 1.1 as determined by investigator's assessment.

    Time frame: Approximately 3 years.

  10. Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)

    To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab. TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function.

    Time frame: Approximately 3 years.

  11. Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.

    To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab. TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden.

    Time frame: Approximately 3 years.

07

Study locations

231 of 231 sites recruiting

Showing the first 100 of 231 sites across 28 countries. Choose a country and city above to see the rest.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Apr 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 23, 2025
StartActual
Jan 28, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Jul 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
230 sites added, 202 sites removed — first sites in Japan and Thailand
Show 230 added (54 United States, 20 Brazil, 18 Italy, 15 United Kingdom, 15 Germany, 11 France, 11 Spain, 8 Australia, 8 Portugal, 7 South Korea, 7 Poland, 6 Belgium, 5 Thailand, 5 Turkey (Türkiye), 5 Argentina, 5 Malaysia, 4 Israel, 4 Taiwan, 3 Canada, 3 Ireland, 3 Switzerland, 2 India, 2 Austria, 2 Czechia, 2 Greece, 2 New Zealand, 2 Singapore, 1 Japan)
  • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127) · Newark, United States
  • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133) · Chicago, United States
  • University of Kentucky, Markey Cancer Center (Site # 109) · Lexington, United States
  • University of Michigan (Site # 161) · Ann Arbor, United States
  • Hackensack Meridian Health (Site # 119) · Hackensack, United States
  • Centro de Tratamento Oncologico (Site # 2421) · Belém, Brazil
  • Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414) · Fortaleza, Brazil
  • Hospital Nossa Senhora da Conceicao (Site # 2403) · Porto Alegre, Brazil
  • Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410) · São Caetano do Sul, Brazil
  • Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417) · São Paulo, Brazil
  • A. C. Camargo Cancer Center (Site # 2409) · São Paulo, Brazil
  • Hospital Santa Marcelina (Site # 2418) · São Paulo, Brazil
  • Meenakshi Mission Hospital & Research Centre (Site # 3003) · Madurai, India
  • Soroka Medical Center (Site # 1901) · Beersheba, Israel
  • Rabin Medical Center (Site # 1904) · Petah Tikva, Israel
  • ARNAS G. Brotzu (Site # 913) · Cagliari, Italy
  • Cancer Institute Hospital of JFCR (Site # 3107) · Kōtoku, Japan
  • Samsung Medical Center (Site # 2703) · Seoul, South Korea
  • Phramongkutklao Hospital (Site # 2505) · Bangkok, Thailand
  • Rajavithi Hospital (Site # 2504) · Bangkok, Thailand
  • Maharaj Nakorn Chiang Mai Hospital (Site # 2506) · Chiang Mai, Thailand
  • Vajira Hospital (Site # 2503) · Dusit, Thailand
  • Songklanagarind Hospital (Site # 2502) · Hat Yai, Thailand
  • Memorial Ankara Hospital (Site # 1202) · Ankara, Turkey (Türkiye)
  • Memorial Antalya Hastanesi (Site # 1204) · Antalya, Turkey (Türkiye)
  • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203) · Istanbul, Turkey (Türkiye)
  • Dokuz Eylul University Medical School (Site # 1206) · Izmir, Turkey (Türkiye)
  • Newcastle University (Site # 509) · Newcastle upon Tyne, United Kingdom
  • University of Alabama Hospital (Site # 0137) · Birmingham, United States
  • Mayo Clinic Hospital (Site #0147) · Phoenix, United States
  • …and 200 more on the registry record
Show 202 removed
  • Site # 0137 · Birmingham, United States
  • Site #0147 · Phoenix, United States
  • Site #0107 · La Jolla, United States
  • Site #0106 · Los Angeles, United States
  • Site#0144 · Sacramento, United States
  • Site #0130 · San Francisco, United States
  • Site #0150 · Stanford, United States
  • Site #0122 · Aurora, United States
  • Site #0124 · Aurora, United States
  • Site#0121 · Aurora, United States
  • Site #0148 · Jacksonville, United States
  • Site #0136 · Palm Bay, United States
  • Site #0105 · Tampa, United States
  • Site#0140 · Iowa City, United States
  • Site #0149 · Westwood, United States
  • Site#0111 · Louisville, United States
  • Site#0115 · Louisville, United States
  • Site #0112 · Baltimore, United States
  • Site #0131 · Boston, United States
  • Site#0101 · Boston, United States
  • Site #0146 · Rochester, United States
  • Site #0114 · St Louis, United States
  • Site #0145 · Newark, United States
  • Site #0155 · New York, United States
  • Site#0142 · New York, United States
  • Site#0118 · Durham, United States
  • Site#0154 · Canton, United States
  • Site#0117 · Cincinnati, United States
  • Site #0151 · Cleveland, United States
  • Site #0108 · Cleveland, United States
  • …and 172 more on the registry record
across 2 updates, Oct 2, 2026 – Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    202 sites added, 202 sites removed
    Show 202 added (49 United States, 17 Italy, 15 Germany, 14 United Kingdom, 13 Brazil, 11 France, 11 Spain, 8 Australia, 8 Portugal, 7 Poland, 6 Belgium, 6 South Korea, 5 Argentina, 5 Malaysia, 4 Taiwan, 3 Canada, 3 Ireland, 3 Switzerland, 2 Austria, 2 Czechia, 2 Greece, 2 Israel, 2 New Zealand, 2 Singapore, 1 India, 1 Turkey (Türkiye))
    • University of Alabama Hospital (Site # 0137) · Birmingham, United States
    • Mayo Clinic Hospital (Site #0147) · Phoenix, United States
    • UC San Diego Moores Cancer Center (Site #0107) · La Jolla, United States
    • UCLA Department of Medicine - Hematology/Oncology (Site #0106) · Los Angeles, United States
    • UC Davis (Site#0144) · Sacramento, United States
    • University of California San Francisco (Site #0130) · San Francisco, United States
    • Stanford Cancer Institute (Site #0150) · Stanford, United States
    • Rocky Mountain Cancer Centers, LLP (Site #0122) · Aurora, United States
    • Rocky Mountain Regional VAMC (Site #0124) · Aurora, United States
    • University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121) · Aurora, United States
    • Mayo Clinic Florida (Site #0148) · Jacksonville, United States
    • Cancer Care Centers of Brevard (Site #0136) · Palm Bay, United States
    • Moffit Cancer Center (Site #0105) · Tampa, United States
    • University of Iowa Hospitals & Clinics (Site#0140) · Iowa City, United States
    • University of Kansas Medical Center Research Institute, Inc. (Site #0149) · Westwood, United States
    • Norton Cancer Institute (Site#0111) · Louisville, United States
    • The University of Louisville, James Graham Brown Cancer Center (Site#0115) · Louisville, United States
    • University of Maryland Medical Group (Site #0112) · Baltimore, United States
    • Massachusetts General Hospital (Site #0131) · Boston, United States
    • Dana-Farber Cancer Institute (Site#0101) · Boston, United States
    • Mayo Clinic Cancer Center - Rochester (Site #0146) · Rochester, United States
    • Washington University School of Medicine (Site #0114) · St Louis, United States
    • Rutgers- Cancer Institute (Site #0145) · Newark, United States
    • Mount Sinai (Site #0155) · New York, United States
    • Memorial Sloan Kettering Cancer Center (Site#0142) · New York, United States
    • Duke University Health System (Site#0118) · Durham, United States
    • Mercy Hospital (Site#0154) · Canton, United States
    • University of Cincinnati Cancer Institute (Site#0117) · Cincinnati, United States
    • University Hospitals Seidman Cancer Center (Site #0151) · Cleveland, United States
    • Cleveland Clinic (Site #0108) · Cleveland, United States
    • …and 172 more on the registry record
    Show 202 removed
    • Site # 0137 · Birmingham, United States
    • Site #0147 · Phoenix, United States
    • Site #0107 · La Jolla, United States
    • Site #0106 · Los Angeles, United States
    • Site#0144 · Sacramento, United States
    • Site #0130 · San Francisco, United States
    • Site #0150 · Stanford, United States
    • Site #0122 · Aurora, United States
    • Site #0124 · Aurora, United States
    • Site#0121 · Aurora, United States
    • Site #0148 · Jacksonville, United States
    • Site #0136 · Palm Bay, United States
    • Site #0105 · Tampa, United States
    • Site#0140 · Iowa City, United States
    • Site #0149 · Westwood, United States
    • Site#0111 · Louisville, United States
    • Site#0115 · Louisville, United States
    • Site #0112 · Baltimore, United States
    • Site #0131 · Boston, United States
    • Site#0101 · Boston, United States
    • Site #0146 · Rochester, United States
    • Site #0114 · St Louis, United States
    • Site #0145 · Newark, United States
    • Site #0155 · New York, United States
    • Site#0142 · New York, United States
    • Site#0118 · Durham, United States
    • Site#0154 · Canton, United States
    • Site#0117 · Cincinnati, United States
    • Site #0151 · Cleveland, United States
    • Site #0108 · Cleveland, United States
    • …and 172 more on the registry record
    + 1 other change: verification date
  2. Oct 2, 2026
    28 sites added — first sites in Japan and Thailand
    Show 28 added (7 Brazil, 5 United States, 5 Thailand, 4 Turkey (Türkiye), 2 Israel, 1 India, 1 Italy, 1 Japan, 1 South Korea, 1 United Kingdom)
    • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127) · Newark, United States
    • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133) · Chicago, United States
    • University of Kentucky, Markey Cancer Center (Site # 109) · Lexington, United States
    • University of Michigan (Site # 161) · Ann Arbor, United States
    • Hackensack Meridian Health (Site # 119) · Hackensack, United States
    • Centro de Tratamento Oncologico (Site # 2421) · Belém, Brazil
    • Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414) · Fortaleza, Brazil
    • Hospital Nossa Senhora da Conceicao (Site # 2403) · Porto Alegre, Brazil
    • Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410) · São Caetano do Sul, Brazil
    • Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417) · São Paulo, Brazil
    • A. C. Camargo Cancer Center (Site # 2409) · São Paulo, Brazil
    • Hospital Santa Marcelina (Site # 2418) · São Paulo, Brazil
    • Meenakshi Mission Hospital & Research Centre (Site # 3003) · Madurai, India
    • Soroka Medical Center (Site # 1901) · Beersheba, Israel
    • Rabin Medical Center (Site # 1904) · Petah Tikva, Israel
    • ARNAS G. Brotzu (Site # 913) · Cagliari, Italy
    • Cancer Institute Hospital of JFCR (Site # 3107) · Kōtoku, Japan
    • Samsung Medical Center (Site # 2703) · Seoul, South Korea
    • Phramongkutklao Hospital (Site # 2505) · Bangkok, Thailand
    • Rajavithi Hospital (Site # 2504) · Bangkok, Thailand
    • Maharaj Nakorn Chiang Mai Hospital (Site # 2506) · Chiang Mai, Thailand
    • Vajira Hospital (Site # 2503) · Dusit, Thailand
    • Songklanagarind Hospital (Site # 2502) · Hat Yai, Thailand
    • Memorial Ankara Hospital (Site # 1202) · Ankara, Turkey (Türkiye)
    • Memorial Antalya Hastanesi (Site # 1204) · Antalya, Turkey (Türkiye)
    • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203) · Istanbul, Turkey (Türkiye)
    • Dokuz Eylul University Medical School (Site # 1206) · Izmir, Turkey (Türkiye)
    • Newcastle University (Site # 509) · Newcastle upon Tyne, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06788990
Lead sponsor
Bicara Therapeutics
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Jan 28, 2025
Primary completion
Apr 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Medical Affairs
Contact
FORTIFI_inquiries@bicara.com
1-617-468-4219

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ficerafusp alfa

Start the discussion